Citace podle APA (7th ed.)

Montefiori, L. E., Iacobucci, I., Gao, Q., Moore, J., Wright, W. C., Wei, H., . . . Mullighan, C. G. (2025). Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia. Blood, 146(19), 2350. https://doi.org/10.1182/blood.2025028985

Citace podle Chicago (17th ed.)

Montefiori, Lindsey E., et al. "Venetoclax Plus Gilteritinib Is Effective in Preclinical Models of FLT3-mutant BCL11B-a Lineage-ambiguous Leukemia." Blood 146, no. 19 (2025): 2350. https://doi.org/10.1182/blood.2025028985.

Citace podle MLA (9th ed.)

Montefiori, Lindsey E., et al. "Venetoclax Plus Gilteritinib Is Effective in Preclinical Models of FLT3-mutant BCL11B-a Lineage-ambiguous Leukemia." Blood, vol. 146, no. 19, 2025, p. 2350, https://doi.org/10.1182/blood.2025028985.

Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..